US Stock MarketDetailed Quotes
CANF Can-Fite BioPharma
- 2.1000
- +0.0500+2.44%
Close Nov 27 16:00 ET
- 2.1600
- +0.0600+2.86%
Post 18:20 ET
12.80MMarket Cap-808P/E (TTM)
2.2499High2.0700Low86.18KVolume2.1000Open2.0500Pre Close183.56KTurnover1.58%Turnover RatioLossP/E (Static)6.10MShares4.690052wk High5.16P/B11.43MFloat Cap1.866152wk Low--Dividend TTM5.45MShs Float1419.0000Historical High--Div YieldTTM8.78%Amplitude1.5200Historical Low2.1300Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Can-Fite BioPharma Stock Forum
2 MINUTES AGO, 7:08 AM EST
VIA GLOBENEWSWIRE
7 MINUTES AGO, 9:06 AM EDT
VIA GLOBENEWSWIRE
Data Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal worth $325M
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
RAMAT GAN, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the Company’s oncology drug candidate, Namodenoson, has been granted O...
Can-Fite BioPharma treatment of pancreatic cancer granted FDA orphan status
6 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology firm dedicated to developing innovative treatments for oncological and inflammatory diseases, has unveiled new findings concerning its small molecule drug, Namodenoson. These recent discoveries shed light on the mechanisms by which Namodeno...
No comment yet